Literature DB >> 21931981

Secondary Antifungal Prophylaxis in Hematopoietic Stem Cell Transplantation (HSCT)/Acute Leukemia Patients.

Jean El Cheikh1.   

Abstract

In this review, the role of secondary antifungal prophylaxis (SAP) in prevention of invasive fungal infections (IFIs) in patients with leukemia and in those receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT) is discussed. A history of IFI is not an absolute contraindication for allo-HSCT or continuation of cytotoxic chemotherapy, provided that SAP is administered. We suggest that the last antifungal drug successfully used for treatment of the previous IFI is also used for SAP; during SAP, we propose an algorithm of thorough clinical, radiological and microbiological monitoring with monthly CT scan and twice weekly galactomannan assays. However, the optimal preventive strategy for patients with a prior IFI has not been defined and concerted efforts are warranted to optimize the management of affected patients.

Entities:  

Year:  2011        PMID： 21931981     DOI： 10.1007/s11908-011-0214-8

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


  46 in total

1.  Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen.

Authors:  M Mohty; W Jacot; C Faucher; J O Bay; C Zandotti; L Collet; B Choufi; K Bilger; O Tournilhac; N Vey; A M Stoppa; D Coso; J A Gastaut; P Viens; D Maraninchi; D Olive; D Blaise
Journal:  Leukemia       Date:  2003-11       Impact factor: 11.528

2.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Authors:  Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

3.  Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats.

Authors:  G W Boswell; I Bekersky; D Buell; R Hiles; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

4.  Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B.

Authors:  William H Krüger; Bettina Rüssmann; Maike de Wit; Nicolaus Kröger; Helmut Renges; Ingo Sobottka; Axel R Zander
Journal:  Acta Haematol       Date:  2005       Impact factor: 2.195

5.  Once-weekly liposomal amphotericin B for prophylaxis of invasive fungal infection after graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: a comparative retrospective single-center study.

Authors:  Jean El Cheikh; Luca Castagna; Ling Wang; Benjamin Esterni; Catherine Faucher; Sabine Furst; Segolene Duran; Pierre Berger; Stephane Ranque; Mohamad Mohty; Didier Blaise
Journal:  Hematol Oncol Stem Cell Ther       Date:  2010

6.  High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation.

Authors:  J El-Cheikh; C Faucher; S Fürst; S Duran; P Berger; N Vey; A-M Stoppa; R Bouabdallah; J-A Gastaut; P Viens; D Blaise; M Mohty
Journal:  Bone Marrow Transplant       Date:  2007-01-29       Impact factor: 5.483

7.  Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005.

Authors:  Amar Safdar; Gilhen H Rodriguez; Marcos J De Lima; Demetrios Petropoulos; Roy F Chemaly; Laura L Worth; Elizabeth J Shpall; Kenneth V I Rolston; Issam I Raad; Ka Wah Chan; Richard E Champlin
Journal:  Medicine (Baltimore)       Date:  2007-11       Impact factor: 1.889

8.  Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B.

Authors:  G P Bodey; E J Anaissie; L S Elting; E Estey; S O'Brien; H Kantarjian
Journal:  Cancer       Date:  1994-04-15       Impact factor: 6.860

9.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

10.  Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.

Authors:  Wiro B Stam; Amy K O'Sullivan; Bart Rijnders; Elly Lugtenburg; Lambert F R Span; Jeroen J W M Janssen; Jeroen P Jansen
Journal:  Eur J Haematol       Date:  2008-12       Impact factor: 2.997
View more
  1 in total

1.  Fungal pathogens and primary antifungal prophylaxis in patients with hematological malignancies: one year experience.

Authors:  H Gedik; M T Yildirmak; F Simsek; D Aydin; N Demirel; O Yokus; D Arica
Journal:  Afr Health Sci       Date:  2012-09       Impact factor: 0.927
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.